Clinical Trials Logo

Clinical Trial Summary

To assess efficacy of bronchoscopic lung volume reduction in Korean emphysema patients


Clinical Trial Description

The prevalence of chronic obstructive pulmonary disease (COPD) is high (13.4%). In addition, COPD ranked 10th among the causes of death in Korea, and rose to 7th in 2008. Airflow limitation of COPD is caused by a mixture of small airway disease (obstructive bronchiolitis) and parenchyma destruction (emphysema). Bronchodilator and anti-inflammatory drugs, such as corticosteroids are effective to obstructive bronchiolitis. However, these drugs are not effective to emphysema.

Lung volume reduction was devised to remove hyperinflated lung, and to function remaining lung. Surgical lung volume reduction showed improving survival in selected emphysema patients. However, surgical lung volume reduction have bee performed rarely due to significant surgery-related mortality. In this regard, non-surgical lung volume reduction methods have been developed. Of them, bronchoscopic lung volume reduction by endobronchial one-way valve is mostly used method and showed lower early complications than surgery.

The bronchoscopic lung volume reduction using endobronchial valve was proved its efficacy and safety in several large clinical trials. Although there were procedure-related complications such as acute exacerbation of COPD, pneumonia, or hemoptysis, patients receiving endobronchial valves showed improved lung functions, exercise capacity and quality of life. The endobronchial valves got approved for Conformity to European (CE) Mark in Europe. In follow-up study for patients with endobronchial valves, their efficacy and survival of patients were dependent on atelectasis induced by valves. Collateral ventilation plays a key role in endobronchial valve-induced atelectasis. Therefore, assessment of collateral ventilation should be preceded before inserting endobronchial valve.

Computed tomography (CT) can visualize and characterize morphologic change of lung of patients with COPD. Lung perfusion and ventilation CT protocols were developed for quantitative assessment of COPD before and after medical treatment. The CT protocols were expected to select optimal patients for endobronchial valves and to evaluate their efficacy.

We attempt to evaluate efficacy of bronchoscopic lung volume reduction using lung perfusion and ventilation CT and other outcomes. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01869205
Study type Interventional
Source Asan Medical Center
Contact
Status Completed
Phase Phase 3
Start date March 2013
Completion date April 2017

See also
  Status Clinical Trial Phase
Recruiting NCT00995852 - Unilateral Versus Bilateral Endoscopic Lung Volume Reduction A Comparative Case Study Phase 2/Phase 3
Completed NCT01860898 - A Phase I Study of iPS Cell Generation From Patients With COPD N/A
Completed NCT00123422 - Innovation in Pulmonary Rehabilitation N/A
Recruiting NCT02879331 - Clinical Study to Evaluate the Exercise Capacity in Patients With Severe Emphysema Treated With Coils N/A
Completed NCT01507415 - Do the SPPB and 4-metre Gait Speed Predict Hospital Readmission in Patients Hospitalised for Acute Exacerbation if COPD? N/A
Completed NCT01051258 - AeriSeal System for Lung Volume Reduction Phase 1/Phase 2
Completed NCT00680056 - Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients Phase 4
Completed NCT01872624 - Safety Study of Bone-marrow Derived Mesenchymal Stromal Cells Associated With Endobronchial Valves in Emphysema N/A
Completed NCT01110252 - Safety Study of Cell Therapy to Treat Chronic Obstructive Pulmonary Disease N/A
Completed NCT00517998 - Israeli Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study Phase 1
Terminated NCT00205920 - Netherlands 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation Phase 2
Withdrawn NCT01849159 - Clinical Study of the Efficacy and Safety of the Application of Allogeneic Mesenchymal (Stromal) Cells of Bone Marrow, Cultured Under the Hypoxia in the Treatment of Patients With Severe Pulmonary Emphysema Phase 1/Phase 2
Terminated NCT01320566 - A Continuation Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema Phase 2/Phase 3
Completed NCT00683722 - PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Active, not recruiting NCT04465461 - Video Assisted Thoracic Surgery (VATS) Fissure Completion Prior to Zephyr® Endobronchial Valve Insertion N/A
Completed NCT04012359 - Description of Bullous Emphysema Using Lung Ultrasound and Comparison to the Characteristics of Pneumothorax
Recruiting NCT04918706 - Allogeneic MSC Treatment for Pulmonary Emphysema Phase 2
Terminated NCT01449292 - Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE) Phase 3
Completed NCT00347659 - US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study Phase 1
Recruiting NCT02827721 - Evaluation of Novel Lung Function Parameters in Patients With Chronic Obstructive Pulmonary Disease (COPD)